RT Journal Article
SR Electronic
T1 Persistent COVID-19 symptoms minimally impact the development of SARS-CoV-2 specific cellular immunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.29.21250771
DO 10.1101/2021.01.29.21250771
A1 HengSheng Fang
A1 Adam D. Wegman
A1 Kianna Ripich
A1 Heather Friberg
A1 Jeffrey R. Currier
A1 Stephen J. Thomas
A1 Timothy P. Endy
A1 Adam T. Waickman
YR 2021
UL http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250771.abstract
AB SARS-CoV-2 represents an unprecedented public health challenge with many unknowns remaining regarding the factors that impact viral pathogenicity and the development of immunity after infection. While the majority of SARS-CoV-2 infected individuals with mild-to-moderate COVID-19 resolve their infection with few complications, a significant number of individuals experienced prolonged symptoms lasting for weeks after initial diagnosis. Persistent viral infections are commonly accompanied by immunologic dysregulation, especially within the cellular immune compartment. However, it is unclear if persistent mild-to-moderate COVID-19 impacts the development of virus-specific cellular immunity. To this end, we analyzed the development of SARS-CoV-2 specific cellular immunity in convalescent COVID-19 patients who experienced eight days or fewer of COVID-19 symptoms, or symptoms persisting for 18 days or more. We observed that the duration of COVID-19 symptoms minimally impacts the magnitude, antigen specificity, and transcriptional profile of SARS-CoV-2 specific cellular immunity within both the CD4+ and CD8+ T cell compartments. Furthermore, we observed that reactivity against the structural N protein from SARS-CoV-2 in convalescent COVID-19 patients correlates with the amount of reactivity against the seasonal human coronaviruses 229E and NL63. These results provide additional insight into the complex processes that regulate the development of cellular immunity against SARS-CoV-2 and related human coronaviruses.Competing Interest StatementSJT reports other from Pfizer, during the conduct of the study; personal fees from Merck, personal fees from Sanofi, personal fees from Takeda, personal fees from Themisbio, personal fees from Janssen, outside the submitted work. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interestFunding StatementThis work was internally funded by the State University of New York.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the SUNY Upstate Medical University IRB, reviewed approved by the Western Institutional Review Board (IRB # 1587400), and performed under informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors declare that all data supporting the findings of this study are available within this article or from the corresponding author upon reasonable request. RNAseq gene expression data have been deposited in the Gene Expression Omnibus database (GSE165373).